Hikma Pharmaceuticals (LON:HIK) Given New GBX 2,000 Price Target at Deutsche Bank Aktiengesellschaft

Hikma Pharmaceuticals (LON:HIK) had its target price reduced by Deutsche Bank Aktiengesellschaft from GBX 2,050 to GBX 2,000 in a report published on Friday,Digital Look reports. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock.

Other analysts have also recently issued research reports about the company. Berenberg Bank lifted their target price on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Citigroup upped their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,025 target price on shares of Hikma Pharmaceuticals in a research report on Thursday. Four analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Hikma Pharmaceuticals currently has an average rating of “Buy” and an average target price of GBX 1,998.75.

Hikma Pharmaceuticals Stock Performance

HIK traded down GBX 47 on Friday, reaching GBX 1,650. The company had a trading volume of 798,328 shares, compared to its average volume of 4,190,985. Hikma Pharmaceuticals has a 1 year low of GBX 1,187 and a 1 year high of GBX 1,762. The stock has a market capitalization of £3.41 billion, a PE ratio of 9.38, a P/E/G ratio of 2.38 and a beta of 0.65. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57. The stock has a 50-day moving average price of GBX 1,627.89 and a 200-day moving average price of GBX 1,508.93.

Insider Activity

In related news, insider Tobias Hestler purchased 7,500 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of GBX 1,648 per share, with a total value of £123,600. 22.26% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Hikma Pharmaceuticals

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Hikma raised its growth outlook for branded medicines, a positive offset to weakness elsewhere in the business. Hikma Raises Branded Growth Outlook, Narrows 2026 Profit Guidance
• Neutral Sentiment: The company maintained its 2026 revenue guidance and narrowed its operating profit forecast to $740–$760 million. The tighter range gives investors more clarity, but the outlook remains a key focus. Hikma Pharmaceuticals Maintains 2026 Revenue Guidance and Narrows Operating Profit Forecast
• Neutral Sentiment: Jefferies reaffirmed its Buy rating with a GBX 2,025 target, while Deutsche Bank cut its target from GBX 2,050 to GBX 2,000 but retained a Buy rating. Deutsche Bank rating information
• Negative Sentiment: Hikma lowered its outlook for Injectables. That business outlook revision is the clearest near-term headwind and likely weighs on sentiment despite the brighter branded-medicines forecast. Hikma Pharmaceuticals shares down as cuts Injectables outlook

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.